Heron Therapeutics, Inc. (NASDAQ:HRTX) Shares Acquired by New York State Common Retirement Fund

New York State Common Retirement Fund increased its position in Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) by 32.7% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,752,924 shares of the biotechnology company's stock after buying an additional 431,918 shares during the quarter. New York State Common Retirement Fund owned about 1.15% of Heron Therapeutics worth $3,856,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of HRTX. Point72 Asset Management L.P. acquired a new position in Heron Therapeutics during the fourth quarter valued at $4,706,000. Palisade Capital Management LP raised its position in Heron Therapeutics by 34.7% during the first quarter. Palisade Capital Management LP now owns 5,286,931 shares of the biotechnology company's stock valued at $11,631,000 after buying an additional 1,360,542 shares during the period. Stonepine Capital Management LLC acquired a new position in Heron Therapeutics during the fourth quarter valued at $1,071,000. Quinn Opportunity Partners LLC acquired a new position in Heron Therapeutics during the fourth quarter valued at $581,000. Finally, JPMorgan Chase & Co. raised its position in Heron Therapeutics by 172.2% during the fourth quarter. JPMorgan Chase & Co. now owns 562,764 shares of the biotechnology company's stock valued at $861,000 after buying an additional 356,053 shares during the period. Institutional investors and hedge funds own 80.01% of the company's stock.

Heron Therapeutics Stock Performance

Shares of HRTX opened at $1.90 on Wednesday. The stock has a fifty day moving average price of $2.02 and a two-hundred day moving average price of $2.00. Heron Therapeutics, Inc. has a 52-week low of $1.04 and a 52-week high of $3.31. The company has a market cap of $289.86 million, a price-to-earnings ratio of -31.67 and a beta of 1.18.

Heron Therapeutics (NASDAQ:HRTX - Get Free Report) last released its earnings results on Tuesday, May 6th. The biotechnology company reported $0.01 earnings per share for the quarter, topping analysts' consensus estimates of ($0.01) by $0.02. The firm had revenue of $38.90 million for the quarter, compared to the consensus estimate of $37.08 million. As a group, research analysts predict that Heron Therapeutics, Inc. will post -0.13 EPS for the current fiscal year.

Analyst Ratings Changes

HRTX has been the subject of a number of recent research reports. HC Wainwright started coverage on Heron Therapeutics in a research note on Monday, June 9th. They set a "buy" rating and a $6.00 price target for the company. Needham & Company LLC reaffirmed a "buy" rating and issued a $4.00 price target on shares of Heron Therapeutics in a research report on Friday, April 11th. Finally, Wall Street Zen raised Heron Therapeutics from a "hold" rating to a "buy" rating in a research report on Friday, June 6th.

About Heron Therapeutics

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.